Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Marks & Spencer CEO Stuart Machin insisted the high street retailer – which reported a 1% year-on-year rise in clothing and ...

Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

Approximately $50.0 million of net revenue from sales of LUMRYZ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients ...

LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

Lifecore Biomedical, Inc. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.27. Operator: Good ...

Crinetics Pharmaceuticals is set for a fall 2025 launch of paltusotine, with strong Wall Street support despite being ...

The second and more recent probe involves alleged smuggling of unapproved drugs—the Daiichi-partnered HER2 therapy Enhertu ...

The resurgence of the Chinese market triggered a wave of foreign outflows, as investors shifted their focus to the East. Notably, Foreign Institutional Investors (FIIs) continued their selling spree ...

The World Health Organization (WHO), through its Department of Regulation and Prequalification, has issued a call for action to drive sustainability in the pharmaceutical sector. Entitled “Greener ...

In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against other stocks in Jim Cramer’s latest portfolio heading into 2025. Jim Cramer in a latest program ...